Celsion Corporation (NASDAQ:CLSN) will issue its quarterly earnings data before the market opens on Tuesday, November 14th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter.
Celsion Corporation (CLSN) opened at $2.00 on Monday. Celsion Corporation has a 12 month low of $1.24 and a 12 month high of $12.88.
CLSN has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Celsion Corporation from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research note on Tuesday, August 29th. Maxim Group upgraded shares of Celsion Corporation from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Wednesday, October 4th. Finally, ValuEngine upgraded shares of Celsion Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $12.63.
About Celsion Corporation
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.